The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Highly Potent Geminal Bisphosphonates. From Pamidronate Disodium (Aredia) to Zoledronic Acid (Zometa)
Abstract
Bisphosphonates (BPs) are pyrophosphate analogues in which the oxygen in P-O-P has been replaced by a carbon, resulting in a metabolically stable P-C-P structure. Pamidronate (1b, Novartis), a second-generation BP, was the starting point for extensive SAR studies. Small changes of the structure of pamidronate lead to marked improvements of the inhibition of osteoclastic resorption potency. Alendronate (1c, MSD), with an extra methylene group in the N-alkyl chain, and olpadronate (1h, Gador), the N,N-dimethyl analogue, are about 10 times more potent than pamidronate. Extending one of the N-methyl groups of olpadronate to a pentyl substituent leads to ibandronate (1k, Roche, Boehringer-Mannheim), which is the most potent close analogue of pamidronate. Even slightly better antiresorptive potency is achieved with derivatives having a phenyl group linked via a short aliphatic tether of three to four atoms to nitrogen, the second substituent being preferentially a methyl group (e.g., 4g, 4j, 5d, or 5r). The most potent BPs are found in the series containing a heteroaromatic moiety (with at least one nitrogen atom), which is linked via a single methylene group to the geminal bisphosphonate unit. Zoledronic acid (6i), the most potent derivative, has an ED(50) of 0.07 mg/kg in the TPTX in vivo assay after sc administration. It not only shows by far the highest therapeutic ratio when comparing resorption inhibition with undesired inhibition of bone mineralization but also exhibits superior renal tolerability. Zoledronic acid (6i) has thus been selected for clinical development under the registered trade name Zometa. The results of the clinical trials indicate that low doses are both efficacious and safe for the treatment of tumor-induced hypercalcemia, Paget's disease of bone, osteolytic metastases, and postmenopausal osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 858
Fleisch, H., Graham, R., Russell, G., & Francis, M. D. (1969) · Science · doi:10.1126/science.165.3899.1262 · Cited by 758
Francis, M. D., Graham, R., Russell, G., & Fleisch, H. (1969) · Science · doi:10.1126/science.165.3899.1264 · Cited by 608
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
Self-citationBisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Sahni, M., Guenther, H. L., Fleisch, H., Collin, P., & Martin, T. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116422 · Cited by 412
Hughes, D. E., MacDonald, B. R., Russell, R. G., & Gowen, M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114100 · Cited by 357
Schenk, R., Eggli, P., Fleisch, H., & Rosini, S. (1986) · Calcified Tissue International · doi:10.1007/bf02555748 · Cited by 315
Structure-activity relationships of various bisphosphonates
Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., & Hagan, P. (1983) · Calcified Tissue International · doi:10.1007/bf02405012 · Cited by 306
Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
Vitte, C. (1996) · Endocrinology · doi:10.1210/en.137.6.2324 · Cited by 299
Cited by
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Surface Modification Using Phosphonic Acids and Esters
Queffélec, C., Petit, M., Janvier, P., Knight, D. A., & Bujoli, B. (2012) · Chemical Reviews · doi:10.1021/cr2004212 · Cited by 868
Polyoxometalates as Potential Next‐Generation Metallodrugs in the Combat Against Cancer
Bijelic, A., Aureliano, M., & Rompel, A. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201803868 · Cited by 611
The relationship between the chemistry and biological activity of the bisphosphonates
Ebetino, F. H., Hogan, A.-M. L., Sun, S., Tsoumpra, M. K., Duan, X., Triffitt, J. T., Kwaasi, A. A., Dunford, J. E., Barnett, B. L., Oppermann, U., et al. (2011) · Bone · doi:10.1016/j.bone.2011.03.774 · Cited by 391
Nafion phosphonic acid composite membranes for proton exchange membranes fuel cells
Teixeira, F. C., de Sá, A. I., Teixeira, A. P. S., & Rangel, C. M. (2019) · Applied Surface Science · doi:10.1016/j.apsusc.2019.05.078 · Cited by 70
Pavón de Paz, I., Rosado Sierra, J. A., Pérez Blanco, C., Modroño Móstoles, N., Guijarro de Armas, G., & Navea Aguilera, C. (2019) · Endocrinología, Diabetes y Nutrición (English ed.) · doi:10.1016/j.endien.2019.02.001 · Cited by 5
Metadata
- Authors
- Widler, L., Jaeggi, K. A., Glatt, M., Müller, K., Bachmann, R., Bisping, M., Born, A.-R., Cortesi, R., Guiglia, G., Jeker, H., Klein, R., Ramseier, U., Schmid, J., Schreiber, G., Seltenmeyer, Y., & Green, J. R.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-07-19
- Volume
- 45
- Issue
- 17
- Pages
- 3721-3738
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2066342798
- Cited by
- 315
- References
- 25
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.